Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Stroke prevention in atrial fibrillation: Where are we now?

× No keyword cloud information.

22 in total

1. The SAMe-TT2R2 score and quality of anticoagulation in AF: Can we predict which patient benefits from anticoagulation?

Authors: Laurent Fauchier; Daniela Poli; Brian Olshansky
Journal: Thromb Haemost Date: 2015-08-06 Impact factor: 5.249

2. A novel user-friendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation: the Euro Heart Survey.

Authors: Ron Pisters; Deirdre A Lane; Robby Nieuwlaat; Cees B de Vos; Harry J G M Crijns; Gregory Y H Lip
Journal: Chest Date: 2010-03-18 Impact factor: 9.410

3. 2012 focused update of the ESC Guidelines for the management of atrial fibrillation: an update of the 2010 ESC Guidelines for the management of atrial fibrillation--developed with the special contribution of the European Heart Rhythm Association.

Authors: A John Camm; Gregory Y H Lip; Raffaele De Caterina; Irene Savelieva; Dan Atar; Stefan H Hohnloser; Gerhard Hindricks; Paulus Kirchhof
Journal: Europace Date: 2012-08-24 Impact factor: 5.214

Review 4. The global burden of atrial fibrillation and stroke: a systematic review of the epidemiology of atrial fibrillation in regions outside North America and Europe.

Authors: Gregory Y H Lip; Carolyn M Brechin; Deirdre A Lane
Journal: Chest Date: 2012-12 Impact factor: 9.410

5. Oral anticoagulation, aspirin, or no therapy in patients with nonvalvular AF with 0 or 1 stroke risk factor based on the CHA2DS2-VASc score.

Authors: Gregory Y H Lip; Flemming Skjøth; Lars Hvilsted Rasmussen; Torben Bjerregaard Larsen
Journal: J Am Coll Cardiol Date: 2015-03-11 Impact factor: 24.094

Review 6. Unanswered questions and research priorities to optimise stroke prevention in atrial fibrillation with the new oral anticoagulants.

Authors: Graeme J Hankey
Journal: Thromb Haemost Date: 2013-11-28 Impact factor: 5.249

7. Cessation of oral anticoagulation in relation to mortality and the risk of thrombotic events in patients with atrial fibrillation.

Authors: Pilar Gallego; Vanessa Roldan; Francisco Marín; Marta Romera; Mariano Valdés; Vicente Vicente; Gregory Y H Lip
Journal: Thromb Haemost Date: 2013-10-07 Impact factor: 5.249

8. Non-valvular atrial fibrillation patients with none or one additional risk factor of the CHA2DS2-VASc score. A comprehensive net clinical benefit analysis for warfarin, aspirin, or no therapy.

Authors: Gregory Y H Lip; Flemming Skjøth; Peter B Nielsen; Torben Bjerregaard Larsen
Journal: Thromb Haemost Date: 2015-07-30 Impact factor: 5.249

9. Factors affecting quality of anticoagulation control among patients with atrial fibrillation on warfarin: the SAMe-TT₂R₂ score.

Authors: Stavros Apostolakis; Renee M Sullivan; Brian Olshansky; Gregory Y H Lip
Journal: Chest Date: 2013-11 Impact factor: 9.410

Review 10. Vitamin K antagonists in heart disease: current status and perspectives (Section III). Position paper of the ESC Working Group on Thrombosis--Task Force on Anticoagulants in Heart Disease.

Authors: Raffaele De Caterina; Steen Husted; Lars Wallentin; Felicita Andreotti; Harald Arnesen; Fedor Bachmann; Colin Baigent; Kurt Huber; Jørgen Jespersen; Steen Dalby Kristensen; Gregory Y H Lip; João Morais; Lars Hvilsted Rasmussen; Agneta Siegbahn; Freek W A Verheugt; Jeffrey I Weitz
Journal: Thromb Haemost Date: 2013-11-14 Impact factor: 5.249

1 in total

Review 1. Cost-effectiveness of New Oral Anticoagulants for the Prevention of Stroke in Patients with Atrial Fibrillation in Low and Middle-Income Countries: A Systematic Review.

Authors: Aghdas Souresrafil; Ali Abutorabi; Mohammad Mehdi Peighambari; Fereidoun Noohi; Majid Haghjoo
Journal: Med J Islam Repub Iran Date: 2022-02-09

1 in total